Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of intravenous Bondronat loading doses for metastatic bone pain in breast cancer with skeletal metastases
2006-001011-29Phase 2Terminated
- Sponsor
- Roche
- Start
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibandronic acid in bone metastases and breast cancer, sponsored by Roche. Primary endpoint: Bone pain response. Started Aug 2006; status: terminated.
02
Drugs
ibandronic acid
03
Conditions
bone metastasesbreast cancer
Beyond the preview
Go deeper on 2006-001011-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001011-29.